Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced positive results from the Phase 3 tranquility trial, which achieved its primary endpoint of being statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test (p=0.0001) and ≥10 mm Schirmer test responder proportions (p<0.0001)...
Allakos, Inc. (NASDAQ: ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for treatment of inflammatory, and proliferative diseases, faced a setback with disappointing results from a crucial phase 3 trial named Enigma 2 and phase 2/3 Kryptos trial. The studies were evaluating the Company’s...
A clinical stage Immuno-oncology company, Surface Oncology, Inc. (NASDAQ: SURF) is developing a diverse pipeline of candidates that target the immune system to combat various forms of cancer. The Company’s pipeline consists of candidates in four key areas namely macrophages and natural killer cells,...
Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical Company engaged in developing candidates for oncology, auto-immune and chronic pain, has announced the withdrawal of its application for oxycodegol (formerly NKTR-181), as it received adverse advisory committee decision from both Anesthetic and Analgesic Drug Products Advisory Committee, and...
XBiotech Inc (NASDAQ: XBIT), a clinical-stage Biopharmaceutical Company engaged in developing and commercializing True Human monoclonal antibodies, has announced the signing of a definitive agreement with Janssen Biotech, Inc., a pharmaceutical company of Johnson & Johnson (NYSE: JNJ), for the sale of its novel antibody...
